Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of CT102 injection in primary liver cancer
CTR20220933Phase 2Active
- Sponsor
- Hangzhou Tianlong Pharmaceutical
- Start
- May 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CT102 in hepatocellular carcinoma (HCC), sponsored by Hangzhou Tianlong Pharmaceutical. Started May 2022; status: active.
02
Drugs
CT102
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20220933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220933.